Catalyst
Slingshot members are tracking this event:
U.S. Patent Trial and Appeal Board Upholds Biogen's (BIIB) 514 Patent Covering MS Drug Tecfidera (dimethyl fumarate)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BIIB |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 21, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
U.s Patent Trial And Appeal Board, 514, Multiple Sclerosis, Ms, Tecfidera, Dimethyl Fumarate
